|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Profit or loss [abstract] | |||||
| Revenue (Note 18) | |||||
| Cost of sales (Note 5) | |||||
| Loss (gain) on commodity-related derivative financial instruments | |||||
| Commodity-related gain recorded in revenue from risk management and physical derivative contracts | |||||
| Total loss (gain) on commodity-related derivative financial instruments | |||||
| Share of profit from equity accounted investees (Note 10) | |||||
| Gross profit | |||||
| General and administrative | |||||
| Other expense (income) | |||||
| Gain on disposal of assets | |||||
| Loss on acquisition | |||||
| Impairment reversal | |||||
| Results from operating activities | |||||
| Net finance costs (Note 19) | |||||
| Earnings before income tax | |||||
| Current tax expense | |||||
| Deferred tax expense | |||||
| Income tax expense | |||||
| Earnings | |||||
| Earnings attributable to: | |||||
| Shareholders | |||||
| Non-controlling interest | |||||
| Other comprehensive income (loss), net of tax (Note 22) | |||||
| Exchange gain (loss) on translation of foreign operations | |||||
| Impact of hedging activities | |||||
| Re-measurement of defined benefit asset or liability (Note 20) | |||||
| Other comprehensive income (loss), net of tax | |||||
| Total comprehensive income | |||||
| Comprehensive income attributable to: | |||||
| Shareholders | |||||
| Non-controlling interest | |||||
| Earnings attributable to common shareholders, net of preferred share dividends | |||||
| Earnings per common share - basic (in CAD per share) | |||||
| Earnings per common share - diluted (in CAD per share) | |||||
| Weighted average number of common shares (millions) | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...